Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy reiterated a Buy rating on MediciNova with an unchanged $6 price target. The decision is driven by the company's advancing pipeline, including upcoming data from the MN-001 Phase 2 trial for hypertriglyceridemia and NAFLD. Additionally, the MN-166 ALS program's pivotal COMBAT-ALS trial is expected to report results by late 2026, potentially leading to an NDA submission in early 2027. McCarthy views the risk/reward profile as attractive based on these catalysts.
Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Medicinova, retaining the price target of $6.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Jason McCarthy has given his Buy rating due to a combination of factors, including MediciNova’s advancing pipeline and approaching catalysts. He points to the completed Phase 2 trial of MN-001 in patients with hypertriglyceridemia, NAFLD, and type 2 diabetes, where upcoming data on liver fat and triglyceride reduction could validate its multi-pathway mechanism and prior signals of lipid improvement.
McCarthy also emphasizes the MN-166 ALS program, with the pivotal COMBAT-ALS Phase 2b/3 trial expected to deliver topline results by year-end 2026, potentially enabling an NDA submission in the first half of 2027. With additional real-world evidence coming from the SEANOBI expanded-access study and supportive prior safety and efficacy data, he views the overall risk/reward as attractive, maintaining his Buy rating and a $6 price target, which remains unchanged.